Jendle, Johan http://orcid.org/0000-0003-1025-1682
Adolfsson, Peter http://orcid.org/0000-0001-7615-9737
Choudhary, Pratik http://orcid.org/0000-0001-7635-4735
Dovc, Klemen http://orcid.org/0000-0001-9201-2145
Fleming, Alexander http://orcid.org/0000-0002-6549-0288
Klonoff, David C. http://orcid.org/0000-0001-6394-6862
Mader, Julia K. http://orcid.org/0000-0001-7854-4233
Oliver, Nick http://orcid.org/0000-0003-3525-3633
Sherr, Jennifer L. http://orcid.org/0000-0001-9301-3043
Šoupal, Jan http://orcid.org/0000-0001-6041-190X
Heinemann, Lutz http://orcid.org/0000-0003-2493-1304
Funding for this research was provided by:
Medtronic Inc (Medical writing)
Örebro University
Article History
Received: 20 June 2023
Accepted: 5 September 2023
First Online: 2 December 2023
Acknowledgements
: The authors would like to thank O. Cohen and S. de Portu (Medtronic) for their administrative support.
: Open access funding provided by Örebro University. Medtronic commissioned and funded medical writing support. J. Smith-Palmer (Covalence Research, UK) produced the first draft of this article. The authors received no honoraria.
: JJ has been a lecturer/member of the scientific advisory boards at the following companies: Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Medtronic, Nordic InfuCare, NovoNordisk and Sanofi. PA has received speaker’s honoraria from Dexcom, Eli Lilly, Insulet, NovoNordisk, Sanofi and Tandem. He has received consulting fees from and/or held advisory positions with Dexcom, Eli Lilly, Medtronic, NovoNordisk and Roche. PC has received personal fees from Medtronic, Abbott, Dexcom, Lilly, Sanofi, NovoNordisk, Glooko, DreaMed and MannKind. AF is the Executive Chairman of Kinexum, which advises multiple health product companies, including multiple insulin manufacturers. Relevant device companies advised include Abbott, Biolinq, CMC Magnetics, Diabeloop, Hagar, Know Labs, Modular Medical, SFC Fluidics and Surf Bio. He was formerly the Group Leader of the Division of Metabolism and Endocrine Drug Products at the US Food and Drug Administration. DCK is a consultant for Better Therapeutics, EOFlow, Integrity, Lifecare, Nevro, Novo Nordisk, Rockley Photonics and Sanofi. JKM is a member of the advisory boards of Abbott Diabetes Care, Becton Dickinson, Boehringer Ingelheim, Eli Lilly, Embecta, Medtronic, NovoNordisk, Roche Diabetes Care, Sanofi-Aventis and Viatris and has received speaker honoraria from A. Menarini Diagnostics, Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Medtrust, MSD, NovoNordisk, Roche Diabetes Care, Sanofi, Servier and Ypsomed. She is a shareholder of decide Clinical Software GmbH and elyte diagnostics, where she also serves as Chief Medical Officer. KD served on the advisory boards of Novo Nordisk, Pfizer and Sanofi. KD has also received honoraria for participation in the speaker’s bureaus of Abbott, Eli Lilly, Medtronic, NovoNordisk and Pfizer. NO has participated on the advisory boards of Medtronic, Roche Diabetes Care and Dexcom. He has received speaker fees from Dexcom and research funding from Medtronic Diabetes, Roche Diabetes Care and Dexcom. JLS has conducted clinical trials for Eli Lilly, Insulet, Medtronic and Provention Bio and has received in-kind support for research studies from Dexcom and Medtronic. She has consulted for and/or received speaker honoraria from Eli Lilly, Lexicon, Insulet, Medtronic and Zealand. She has been a member of the advisory boards of Bigfoot Biomedical, Cecelia Health, Eli Lilly, Insulet, StartUp Health’s T1D Moonshot, the T1D Fund and Vertex. JŠ has received speaker honoraria from and consulted for Abbott, Dexcom, Eli Lilly, Medtronic, NovoNordisk and Roche. LH holds shares in the Profil Institute for Metabolic Research, Neuss, Germany. LH is also a consultant for embecta, Lifecare and Roche Diabetes Care.
: All authors were responsible for drafting the article and reviewing it critically for important intellectual content. All authors approved the version to be published.